FGD3 mediates lytic cell death, enhancing efficacy and immunogenicity of chemotherapy agents in breast cancer
FGD3 is a key mediator of chemotherapy-induced plasma membrane rupture and lytic cell death. It is also a useful biomarker for identifying breast cancer patients most likely to benefit from lytic cell death-inducing immunogenic anticancer therapies.
Authors
- Matthew W. Boudreau (ORCID: https://orcid.org/0000-0002-2116-1167)
- Chengjian Mao (ORCID: https://orcid.org/0009-0006-4610-7278)
- Paul J. Hergenrother (ORCID: https://orcid.org/0000-0001-9018-3581)
- Yoo Jane Han (ORCID: https://orcid.org/0000-0002-7465-2680)
- Xinyi Dai (ORCID: https://orcid.org/0009-0007-8616-2893)
- David J. Shapiro (ORCID: https://orcid.org/0000-0002-0275-6843)
- Aaron Spaulding (ORCID: https://orcid.org/0000-0001-9727-6756)
- Roger Romero
- Junyao Zhu (ORCID: https://orcid.org/0009-0009-5075-6619)
- Santanu Ghosh (ORCID: https://orcid.org/0000-0001-7201-2498)
- Michael Mulligan (ORCID: https://orcid.org/0000-0003-2457-2962)
- Qianjin Jiang
- Elaine Wei
- Olufunmilayo Olopade
Institutions
- University of Illinois Urbana-Champaign (US)
- University of Chicago (US)
Publication Details
- Journal
- Journal of Experimental & Clinical Cancer Research
- Published
- 2025-11-12
- DOI
- https://doi.org/10.1186/s13046-025-03559-5
- Primary Topic
- Phagocytosis and Immune Regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00